Approval · Notice of Compliance 10662 · 2009
APO-SUMATRIPTAN: Notice of Compliance 10662
Issued October 14, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10662
- Date
- October 14, 2009
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- 5-HT1 receptor agonist, migraine therapy
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-SUMATRIPTAN | 02300567 | Approved |
| APO-SUMATRIPTAN | 02300575 | Approved |
Medicinal ingredients
- SUMATRIPTAN 5 MG per SPR
- SUMATRIPTAN 20 MG per SPR